↓ Skip to main content

Compressing drug development timelines in oncology using phase '0' trials

Overview of attention for article published in Nature Reviews Cancer, February 2007
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)

Mentioned by

policy
1 policy source
patent
2 patents

Citations

dimensions_citation
195 Dimensions

Readers on

mendeley
374 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Compressing drug development timelines in oncology using phase '0' trials
Published in
Nature Reviews Cancer, February 2007
DOI 10.1038/nrc2066
Pubmed ID
Authors

Shivaani Kummar, Robert Kinders, Larry Rubinstein, Ralph E. Parchment, Anthony J. Murgo, Jerry Collins, Oxana Pickeral, Jennifer Low, Seth M. Steinberg, Martin Gutierrez, Sherry Yang, Lee Helman, Robert Wiltrout, Joseph E. Tomaszewski, James H. Doroshow

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 374 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 6 2%
United States 5 1%
Switzerland 3 <1%
Denmark 2 <1%
Czechia 2 <1%
France 1 <1%
South Africa 1 <1%
Ukraine 1 <1%
Australia 1 <1%
Other 4 1%
Unknown 348 93%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 102 27%
Researcher 83 22%
Student > Master 43 11%
Student > Bachelor 24 6%
Professor > Associate Professor 22 6%
Other 71 19%
Unknown 29 8%
Readers by discipline Count As %
Agricultural and Biological Sciences 144 39%
Medicine and Dentistry 77 21%
Biochemistry, Genetics and Molecular Biology 37 10%
Engineering 21 6%
Pharmacology, Toxicology and Pharmaceutical Science 11 3%
Other 50 13%
Unknown 34 9%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 October 2022.
All research outputs
#4,886,384
of 23,505,669 outputs
Outputs from Nature Reviews Cancer
#1,308
of 2,340 outputs
Outputs of similar age
#22,781
of 163,178 outputs
Outputs of similar age from Nature Reviews Cancer
#12
of 18 outputs
Altmetric has tracked 23,505,669 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,340 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.4. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 163,178 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.